Fingolimod exerts in vitro anticancer activity against hepatocellular carcinoma cell lines via YAP/TAZ suppression

Hepatocellular carcinoma (HCC) remains a notably global health challenge with high mortality rates and poor prognosis. The deregulation of the Hippo signalling pathway, especially the overexpression and activation of downstream effector Yes-associated protein (YAP), has been demonstrated to result i...

詳細記述

書誌詳細

主要な著者:	Du Jiamin, Qian Meijia, Yuan Tao, Zhang Bo, Chen Xueqin, An Ning, He Qiaojun, Yang Bo, Ye Song, Zhu Hong
フォーマット:	Artigo
言語:	Inglês
出版事項:	Sciendo 2022-09-01
シリーズ:	Acta Pharmaceutica
主題:	fingolimod hepatocellular carcinoma hippo signalling yap/taz
オンライン･アクセス:	https://doi.org/10.2478/acph-2022-0029
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!